Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Bevacizumab in Patients With Severe Covid-19: a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial

NCT04305106 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.

NCT NCT04305106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04305106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Bevacizumab in Patients With Severe Covid-19: a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial
Lead sponsor
Qilu Hospital of Shandong University
Phase
Phase 3
Overall status
Unknown status
Start date
January 12, 2023
Completion date
December 31, 2023
Enrollment
588 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia